Get instant alerts when breaking news about your stock. Claim your 1 week free trial Street Insider Premium here.
Marinus Pharmaceuticals (Nasdaq: MRNS), a pharmaceutical company dedicated to developing innovative therapies to treat seizure disorders, is led by CEO and Director Scott Brown announced the appointment of Scott Braunstein, MD, as: Board chairman. Dr. Braunstein will succeed Nicole Vituro, who has retired from the Board following his 17-year tenure, which includes the last three years as Chairman.
Marinus also announced two resignations from the board of directors, Michael Dougherty, who retired, and Santiago Arroyo, M.D., who resigned following the announcement of his appointment as Chief Medical Officer of Biotechnology, based in Cambridge, Massachusetts. Announced. Company. The Board has launched a search for replacements for these directors.
Tim M. Maryven, newly appointed Lead Independent Director of Marinus, said:US approval and early commercialization release His ability to articulate and execute on a long-term strategic vision, including the developer of ZTALMY® (ganaxolone) and the strong clinical pipeline of Marinus. On behalf of the Board, I would like to thank Nicole for her unwavering dedication to Marinus over the years and for the many milestones she has achieved during his tenure, and to acknowledge and thank Michael and Santiago for their many contributions. I think. I look forward to complementing the Board’s skills and expertise with new members to support Marinus’ efforts to scale. ”
Chairman and CEO Scott Braunstein said: “I am grateful for the continued support of our major shareholders for our program in this transition and am encouraged by the progress achieved to date in executing our strategy. We believe we can strengthen our commitment to improving the lives of patients with seizure disorders based on We have a chance to let go.”
Dr. Braunstein has been CEO of Marinus since August 2019 and brings nearly 30 years of diverse biopharmaceutical expertise. Most recently, Scott served as Chief Strategy Officer and Chief Operating Officer at Pacira Biosciences, Inc. Prior to that, he spent 13 years at JP Morgan as a Portfolio Manager for the Global Healthcare Fund and as a Healthcare Analyst for the U.S. and Global Equities He team. Dr. Braunstein has served on the boards of several public biotechnology companies for nearly 10 years, and currently serves on the boards of Trevena, Inc. and Caribou Biosciences, Inc. Albert He has worked as a clinical assistant professor at the Einstein College of Medicine and Columbia University Medical Center.
